Dose Insider / Glossary / SURMOUNT-OSA

SURMOUNT-OSAThe sleep apnea trials of tirzepatide

Updated November 20, 2026 · 3 min read · Malhotra et al., N Engl J Med 2024; ZEPBOUND label

SURMOUNT-OSA is a pair of trials that tested tirzepatide for obstructive sleep apnea in adults with obesity. Together they enrolled 469 people with moderate to severe sleep apnea, one trial in people not using a breathing machine at night and one in people who were, and followed them for 52 weeks.

−29.3With PAP, Tirzepatide, fall in breathing events an hour
Fall in breathing events an hourApnea-hypopnea index, week 52WITHOUT PAPTirzepatide−25.3Placebo−5.3WITH PAPTirzepatide−29.3Placebo−5.5Fall in breathing events anhourApnea-hypopnea index, week 52WITHOUT PAPTirzepatide−25.3Placebo−5.3WITH PAPTirzepatide−29.3Placebo−5.5

People started at about 50 events an hour.

On this page

The number of breathing pauses and shallow breaths an hour fell by 25.3 and 29.3 on tirzepatide, against about 5 on placebo. The results led to Zepbound's approval for sleep apnea and were published in the New England Journal of Medicine in 2024.1,2

The measure: the apnea-hypopnea index

Sleep apnea is graded by the apnea-hypopnea index, or AHI: the number of apneas, pauses in breathing, and hypopneas, shallow breaths, during an hour of sleep.1 The trials enrolled people with an AHI of 15 or more, moderate to severe apnea, and a body mass index of 30 or more.2 At the start, the average AHI was 51.5 in the first trial and 49.5 in the second, with average body mass indexes of 39.1 and 38.7.1

How the trials were run

Trial 1 enrolled people who were not using positive airway pressure, the breathing machine often prescribed for sleep apnea; trial 2 enrolled people who were using it. The label gives their sizes as 234 and 235 people. In both, participants were assigned in equal numbers to the highest dose of tirzepatide they tolerated, 10 mg or 15 mg, or placebo, for 52 weeks.1

What they found

Malhotra et al., 2024.1

The Zepbound label adds detail from the same trials. Remission or mild apnea without symptoms was reached by 42.2% on tirzepatide against 15.9% on placebo in the first trial, and 50.2% against 14.3% in the second. The label defines that as an AHI under 5, or an AHI of 5 to 14 with a score of 10 or less on the Epworth Sleepiness Scale, a questionnaire about how easily a person dozes off in daily situations. Weight fell by 17.7% and 19.6% on tirzepatide, against 1.6% and 2.3% on placebo.2

What it changed

On the basis of these trials, Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and more physical activity. For sleep apnea the maintenance dose is 10 mg or 15 mg a week.2 Mounjaro, the same molecule for type 2 diabetes, does not carry this use.3

How to read the result

A fall from about 50 to about 22 or 25 events an hour is large, but for many people it still leaves an AHI above 15, the threshold for moderate apnea. That is why the second trial matters: people who kept using their machine still gained from tirzepatide. Whether someone can stop using their machine is a question for their sleep doctor and a repeat sleep study, not something the trial result decides.

Side effects

The most frequent adverse events with tirzepatide were in the stomach and gut.1 Our Zepbound side effects timeline shows when they tend to start and fade.

Limits

The trials lasted one year and enrolled people with obesity only, so they do not show whether tirzepatide helps sleep apnea in people of lower weight. They were funded by Eli Lilly, the maker of tirzepatide.1

Sources

  1. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205. Funded by Eli Lilly; NCT05412004. doi:10.1056/NEJMoa2404881
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 6.1 and 14.2. accessdata.fda.gov
  3. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov

Related analyses

Log your weight and how you sleep, and see whether they move together.

Open Dose Insider